356 related articles for article (PubMed ID: 11125238)
1. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.
Almkvist O; Jelic V; Amberla K; Hellström-Lindahl E; Meurling L; Nordberg A
Dement Geriatr Cogn Disord; 2001; 12(1):22-32. PubMed ID: 11125238
[TBL] [Abstract][Full Text] [Related]
2. The apolipoprotein E epsilon4 allele and the response to tacrine therapy in Alzheimer's disease.
Rigaud AS; Traykov L; Caputo L; Guelfi MC; Latour F; Couderc R; Moulin F; de Rotrou J; Forette F; Boller F
Eur J Neurol; 2000 May; 7(3):255-8. PubMed ID: 10886308
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein E genotype and gender influence response to tacrine therapy.
Farlow MR; Lahiri DK; Poirier J; Davignon J; Hui S
Ann N Y Acad Sci; 1996 Dec; 802():101-10. PubMed ID: 8993489
[TBL] [Abstract][Full Text] [Related]
4. Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients.
Stefanova E; Blennow K; Almkvist O; Hellström-Lindahl E; Nordberg A
Neurosci Lett; 2003 Feb; 338(2):159-63. PubMed ID: 12566177
[TBL] [Abstract][Full Text] [Related]
5. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease.
Farlow MR; Lahiri DK; Poirier J; Davignon J; Schneider L; Hui SL
Neurology; 1998 Mar; 50(3):669-77. PubMed ID: 9521254
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease.
Poirier J; Delisle MC; Quirion R; Aubert I; Farlow M; Lahiri D; Hui S; Bertrand P; Nalbantoglu J; Gilfix BM; Gauthier S
Proc Natl Acad Sci U S A; 1995 Dec; 92(26):12260-4. PubMed ID: 8618881
[TBL] [Abstract][Full Text] [Related]
7. Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy.
Alhainen K; Riekkinen PJ
Acta Neurol Scand Suppl; 1993; 149():16-21. PubMed ID: 7907454
[TBL] [Abstract][Full Text] [Related]
8. Combined tacrine and estrogen replacement therapy in patients with Alzheimer's disease.
Schneider LS; Farlow M
Ann N Y Acad Sci; 1997 Sep; 826():317-22. PubMed ID: 9329702
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C
Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669
[TBL] [Abstract][Full Text] [Related]
10. An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer's disease. The Tacrine 970-6 Study Group.
Foster NL; Petersen RC; Gracon SI; Lewis K
Dementia; 1996; 7(5):260-6. PubMed ID: 8872417
[TBL] [Abstract][Full Text] [Related]
11. Tacrine and rate of progression in Alzheimer's disease--relation to ApoE allele genotype.
Sjögren M; Hesse C; Basun H; Köl G; Thostrup H; Kilander L; Marcusson J; Edman A; Wallin A; Karlsson I; Troell M; Wachtmaister G; Ekdahl A; Olofsson H; Sandström A; Andreasen N; Minthon L; Blennow K
J Neural Transm (Vienna); 2001; 108(4):451-8. PubMed ID: 11475012
[TBL] [Abstract][Full Text] [Related]
12. Acetylcholinesterase inhibition in dementia with Lewy bodies: results of a prospective pilot trial.
Querfurth HW; Allam GJ; Geffroy MA; Schiff HB; Kaplan RF
Dement Geriatr Cogn Disord; 2000; 11(6):314-21. PubMed ID: 11044776
[TBL] [Abstract][Full Text] [Related]
13. The ability of THA treatment to increase cortical alpha waves is related to apolipoprotein E genotype of Alzheimer disease patients.
Riekkinen P; Soininen H; Partanen J; Pääkkönen A; Helisalmi S; Riekkinen P
Psychopharmacology (Berl); 1997 Feb; 129(3):285-8. PubMed ID: 9084068
[TBL] [Abstract][Full Text] [Related]
14. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.
Aerssens J; Raeymaekers P; Lilienfeld S; Geerts H; Konings F; Parys W
Dement Geriatr Cogn Disord; 2001; 12(2):69-77. PubMed ID: 11173877
[TBL] [Abstract][Full Text] [Related]
15. Frontal dysfunction blocks the therapeutic effect of THA on attention in Alzheimer's disease.
Riekkinen P; Riekkinen M; Soininen H; Kuikka J; Laakso M; Riekkinen P
Neuroreport; 1997 May; 8(8):1845-9. PubMed ID: 9223063
[TBL] [Abstract][Full Text] [Related]
16. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration.
Qizilbash N; Whitehead A; Higgins J; Wilcock G; Schneider L; Farlow M
JAMA; 1998 Nov; 280(20):1777-82. PubMed ID: 9842955
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment postural blood pressure drop as a possible predictor of response to the cholinesterase inhibitor velnacrine (HP 029) in Alzheimer's disease.
Pomara N; Deptula D; Singh R
Psychopharmacol Bull; 1991; 27(3):301-7. PubMed ID: 1775603
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
[TBL] [Abstract][Full Text] [Related]
20. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
Darreh-Shori T; Almkvist O; Guan ZZ; Garlind A; Strandberg B; Svensson AL; Soreq H; Hellström-Lindahl E; Nordberg A
Neurology; 2002 Aug; 59(4):563-72. PubMed ID: 12196650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]